Best moment of the day yesterday at the @WorldPDCongress was interviewing early career researchers Senegal Mabry @Cornell & Sophie Meyer @predictpdstudy about their research on #Parkinsons - it was great fun!

Apply now: MDS Task Force on Parkinson’s Disease Exposome Integration Contribute to an important initiative focused on environmental, lifestyle, genetic, and clinical factors in PD. form.jotform.com/26116508465…

#PureAutonomicFailure carries an annual phenoconversion rate of 5% to central a-synucleinopathies including #ParkinsonDisease, #MSA, and #DLB; subtle motor signs and REM sleep behavior disorder consistently predict conversion risk. ja.ma/4nhZCw1

From autonomic failure to Parkinson’s and beyond: tracking the early warning signs of synuclein related disease. Phenoconversion means the transition from one clinical condition to another over time, in this case from pure autonomic failure to disorders like Parkinson’s disease, dementia with Lewy bodies or multiple system atrophy. Virameteekul and colleagues describe in a new paper in JAMA Neurology how frequently and under what conditions folks w/ pure autonomic failure develop central α-synucleinopathies. Key points: - Approximately 30% of individuals w/ pure autonomic failure developed a central α-synucleinopathy over follow-up, w/ an annual conversion rate of about 5%. - Multiple system atrophy tended to emerge earlier, while Parkinson’s disease and dementia with Lewy bodies showed a more gradual and sustained risk over time. - Clinical features such as REM sleep behavior disorder, subtle motor signs and hyposmia (smell loss) were among the most consistent predictors of conversion. My take: This study reinforces something many of us have suspected for years: the autonomic nervous system may be one of the earliest windows into neurodegeneration. The ability to identify who is at highest risk and when conversion may occur could reshape how we think about early diagnosis and intervention. Here are 5 points that resonated w/ me: 1- Autonomic symptoms may represent an early stage of Parkinson’s biology rather than a separate condition. 2- A 5% annual conversion rate is meaningful and highlights the need for close longitudinal follow-up. 3- Timing matters as different diseases emerge on different trajectories. 4- Simple clinical features like smell loss and dream enactment may help stratify risk today. 5- The future will likely combine clinical signs w/ biomarkers to identify the right folks for early intervention and disease modifying trials. cutt.ly/DtXwCc8u @JAMANetwork @jamaneuro @ParkinsonDotOrg #parkinson

💬 Editorial: #PureAutonomicFailure is firmly established as prodromal for central a-synucleinopathies, with mild motor signs, REM sleep behavior disorder, and bladder symptoms reliably predicting conversion to #ParkinsonDisease, #MSA, or #DLB. ja.ma/3QHz4It

Findings of a systematic review & meta-analysis (9 longitudinal cohorts; n=900; 6.4 yrs follow-up) finds that pure autonomic failure "may be a prodromal presentation of #Parkinsons, DLB, or MSA with phenoconversion incidence rates similar to those of RBD" jamanetwork.com/journals/jam…

📢New clinical research fellow post focused on developing, implementing, and evaluating a psychosocial support programme for people affected by nitrous oxide related harms funded by @Barts_Charity at @preventiveneur1 qmul-jobs.tal.net/vx/mobile-…

We're teaming up with @MichaelJFoxOrg for a major £1.7 million partnership! Introducing the Parkinson’s Clinical Cohorts Collaborative (PC3) – creating a powerful dataset from over 20,000 people to better understand Parkinson’s. Read the full story: prksn.uk/40uco02

📢Advertising new coordinator position for the @predictpdstudy funded by @ParkinsonsUK Please check out details below qmul-jobs.tal.net/vx/mobile-…

Huge thank you Alastair @predictPD for you time to record this podcast to hear was has been learnt over the last 15 years and how this study is informing the direction of future research.

Very exciting to present our @LDCSPD findings at annual Global Parkinson’s Genetics Program (GP2) meeting! Special thanks @predictPD, @EastLondonPD, and our collaborator Dhaka team Prof Ahsan Habib @tahiramou Dr Sirajul Haque and team 😊

Very grateful to @CureParkinsonsT for highlighting this recent work led by @Alex_Zirra and @Kamalesh_Dey Improving diversity in Parkinson’s research – The East London Parkinson’s Disease Project cureparkinsons.org.uk/2025/0…

🚨Fantastic job opportunity for neurology trainees @ABNTrainees Neurology Clinical Lecturer post in Dementia with us @preventiveneur1 @QMUL_WIPH @NHSBartsHealth now open to applications! Please DM me for info and to discuss oriel.nhs.uk/Web/PermaLink/V…

This is a PHENOMENAL course about living with Parkinson's for people & their families but also for neurologists, nurses, health professionals, healthcare students & researchers. A major part is learning from the lived experience of people with PD. It also facilitates research. 🤓

Pls RT 😊Come and join the new #Parkinsons #MOOC community ! ~6000 enrolments in the first 6 days of opening - and great feedback! ⭐️⭐️⭐️⭐️⭐️This visual based online course is packed with videos and animations 🎬 - gives incredible education and insight into lived experience ✅

Pls RT 🤩🎉Fantastic launch of the #Parkinsons #MOOC this week 👏 ✅4,000 people from >30 countries have completed it in the first 3 days! Grab your📲 or 💻 and join this video-based interactive course to see why it’s getting rave reviews! ⭐️⭐️⭐️⭐️⭐️ mooc.utas.edu.au/course/2027…

Ruth Dobson is a Professor of Clinical Neurology and Centre Lead at the Centre for Preventive Neurology (CPN). With our support, the team was established in 2017 and works on revolutionary research into Parkinson's disease, dementia and MS. @drruthdobson's work focuses on Multiple Sclerosis (MS) and their key risk factors, with a particular interest in MS in pregnancy. Find out more on bit.ly/3CBDCJz @QMUL

Charles Marshall is a Professor of Clinical Neurology and dementia expert at the Centre for Preventive Neurology (CPN). With our support, the team was established in 2017 and works on revolutionary research into Parkinson's disease, dementia and MS. @charl_marshall is leading research which explores key risk factors in developing dementia and ways of getting a quick diagnosis for patients. Find out more on bit.ly/3CBDCJz @QMUL

🎉Exciting News!🎉 The launch of our FREE #Parkinson’s #MOOC on Feb 5! Join us for the launch: Register ⭐️utas.zoom.us/webinar/registe… Ready to enhance your understanding and care for Parkinson’s? 👉🏻Sign up today: Register Here shorturl.at/QY9uY

📢#GP2 training & networking coordinator job based @preventiveneur1 Fun international team delivering training opportunities and workshops around the world focused on #parkinsons genetics qmul-jobs.tal.net/vx/candida… @ASAP_Research @MichaelJFoxOrg @ParkinsonsUK @CureParkinsonsT